Jacqueline Olin, MS, PharmD, Assistant Dean and Associate Professor, Wingate University School of Pharmacy
•I have lectured on the topic to pharmacy students, medical residents, and pharmacists
•I have published drug reviews on the topic
PRESENTER(S):
Jacqueline Olin, MS, PharmD, Assistant Dean and Associate Professor, Wingate University School of Pharmacy
•I have lectured on the topic to pharmacy students, medical residents, and pharmacists
•I have published drug reviews on the topic
Linda Spooner, PharmD, BCPS, Assistant Professor of Pharmacy Practice, Massachusetts College of Pharmacy & Health Sciences
Dr. Spooner received her Bachelor of Science in Pharmacy from the University of Connecticut and her Doctor of Pharmacy degree from the University of Oklahoma. She completed a specialty residency in internal medicine pharmacy practice at the University of Texas at Austin/Brackenridge Hospital. Dr. Spooner is a board certified pharmacotherapy specialist, with added qualifications in infectious diseases. She maintains a clinical practice in infectious diseases and internal medicine at Saint Vincent Hospital in Worcester. She also participates in a weekly HIV clinic at the UMASS Family Health Center in Worcester.
Dr. Spooner’s interests include infectious diseases, with emphasis in the pharmacotherapy of HIV infection. In addition to publishing textbook chapters and articles reviewing antiretroviral drug therapy, Dr. Spooner has participated in numerous research projects involving HIV-positive patients, including evaluation of macaroon cookies for treatment of protease inhibitor-induced diarrhea and assessment of pharmacists’ antiretroviral knowledge. She also provides continuing education presentations on HIV pharmacotherapy at numerous regional and national programs.
Describe the pharmacological management of HIV-positive individuals.
Explain common adverse drug events with antiretroviral medications in inpatients with HIV.
Identify key factors to consider when selecting antiretroviral medications for HIV-positive individuals.
State the place in therapy for newly approved antiretroviral medications, including entry inhibitors and integrase inhibitors.